Article
A PDE3A-SLFN12 Molecular Glue Exhibits Significant Antitumor Activity in TKI-Resistant Gastrointestinal Stromal Tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Aug 2024
Takaki Emiri O, Kiyono Kunihiko, Obuchi Yutaka, Yamauchi Takeshi, Watanabe Takashi, Matsumoto Hideki, Karimine Miho, Kuniyoshi Yuki, Nishikori Shingo, Yokoyama Fumiharu, Nishimori Hikaru, Nabeshima Hiroshi, Nakamura Kazuhide
Abstract excerpt
PURPOSE: Gastrointestinal stromal tumor (GIST), the most common mesenchymal tumor with KIT or PDGFRA driver mutations, is typically treated with tyrosine kinase inhibitors (TKI). However, resistance to TKIs due to secondary mutations is a common challenge in advanced GISTs. In addition, there are currently no effective therapies for several other molecular subtypes, such as succinate dehydrogenase-deficient...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
